“Path CR in triple-negative and HER2 disease is very consistent with good or bad prognosis, and predictive of need for more treatments... whereas for ER positive disease, path CR to me wouldn’t be as accurate as I’m not sure what that means.”“Because the percentage of [ER+] patients that achieve a path CR is so much lower, it’s just hard to analyze and really know whether it actually holds like it does for other tumor biologies.” This evidence concerns the gene ERBB2 and neoplasm.